Efficacy of Isradipine in Early Parkinson Disease

Completed · Phase 3 · Has a placebo group

Conditions studied: Parkinson Disease

In brief

The purpose of the study is to determine whether treatment with isradipine is effective in slowing the progression of Parkinson disease disability.

Key facts

Study ID

NCT02168842

Run by

University of Rochester

People needed

336

Starts

2014-11-01

Expected to finish

2018-11-01

Last updated by the study team

2020-01-14

Who can join

Age: 30 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Subjects with early idiopathic PD (presence of at least two out of three cardinal manifestations of PD). If tremor is not present, subjects must have unilateral onset and persistent asymmetry of the symptoms
• Age equal or greater than 30 years at the time of diagnosis of PD
• Hoehn and Yahr stage less than or equal to 2
• Diagnosis of PD less than 3 years.
• Currently NOT receiving dopaminergic therapy (levodopa, dopamine agonist or MAO-B inhibitors) and NOT projected to require PD symptomatic therapy for at least 3 months from the baseline visit
• Use of amantadine and/or anticholinergics will be allowed provided that the dose is stable for 8 weeks prior to the baseline visit
• If subject is taking any central nervous system acting medications (e.g., benzodiazepines, antidepressants, hypnotics) regimen must be stable for 30 days prior to the baseline visit
• Women of childbearing potential may enroll but must use a reliable measure of contraception and have a negative serum pregnancy test at the screening visit

You may not qualify if…

• Subjects with a diagnosis of an atypical Parkinsonism
• Subjects unwilling or unable to give informed consent
• Exposure to dopaminergic PD therapy within 60 days prior to baseline visit or for consecutive 3 months or more at any point in the past
• History of clinically significant orthostatic hypotension or presence of orthostatic hypotension at the screening or baseline visit defined as greater than or equal to 20 mmHg change in systolic BP and greater than or equal to 10 mmHg change in diastolic BP from sitting position to standing after 2 minutes, or baseline sitting BP less than 90/60
• History of congestive heart failure
• Clinically significant bradycardia
• Presence of 2nd or 3rd degree atrioventricular block or other significant ECG abnormalities that in the investigator's opinion would compromise participation in study
• Clinically significant abnormalities in the Screening Visit laboratory studies or ECG
• Presence of other known medical or psychiatric comorbidity that in the investigator's opinion would compromise participation in the study
• Prior exposure to isradipine or other dihydropyridine calcium channel blockers within 6 months of the baseline visit
• Subjects on greater than 2 concomitant antihypertensive medications. If a history of hypertension, then a maximum of 2 other antihypertensive agents will be allowed provided that the dosages of concomitant anti HTN therapy can be reduced/adjusted during the study based on the BP readings in consultation with the subject's primary care provider or cardiologist. Use of any concomitant calcium channel blockers will not be allowed from the baseline visit and for the duration of the study
• Use of grapefruit juice, ginkgo biloba, St. John's wort or ginseng will be prohibited starting from the screening visit and for the duration of the study (as they interfere with the metabolism of isradipine)
• Use of clarithromycin, telithromycin and erythromycin will be prohibited starting from the screening visit and for the duration of the study as the combination of clarithromycin, telithromycin or erythromycin and calcium channel blockers has been reported to be associated with increased risk of kidney and heart injury
• Presence of cognitive dysfunction defined by a Montreal Cognitive assessment (MoCA) score of less than 26 at screening
• Subjects with clinically significant depression as determined by a Beck Depression Inventory II (BDI) score greater than 15 at the screening visit
• History of exposure to typical or atypical antipsychotics or other dopamine blocking agents within 6 months prior to the baseline visit
• History of use of an investigational drug within 30 days prior to the screening visit
• History of brain surgery for PD
• Allergy/sensitivity to isradipine or its matching placebo or their formulations
• Pregnant or lactating woman

Where it is running

• Banner Sun Health Research Institute — Sun City, Arizona, United States
• The Parkinsons & Movement Disorder Institute — Fountain Valley, California, United States
• University of California — Irvine, California, United States
• University of California San Diego — San Diego, California, United States
• University of California, San Francisco — San Francisco, California, United States
• Rocky Mountain Movement Disorders Center — Englewood, Colorado, United States
• Institute of Neurodegenerative Disorders — New Haven, Connecticut, United States
• University of Miami — Miami, Florida, United States
• University of South Florida — Tampa, Florida, United States
• Emory University School of Medicine — Atlanta, Georgia, United States
• Pacific Health Research & Education Institute — Honolulu, Hawaii, United States
• Northwestern University — Chicago, Illinois, United States
• Rush University Medical Center — Chicago, Illinois, United States
• University of Kentucky Medical Center — Lexington, Kentucky, United States
• LSU Health Science Center — Shreveport, Louisiana, United States
• University of Maryland — Baltimore, Maryland, United States
• Johns Hopkins University — Baltimore, Maryland, United States
• Massachusetts General Hospital — Boston, Massachusetts, United States
• Boston University Medical Center — Boston, Massachusetts, United States
• University of Michigan — Ann Arbor, Michigan, United States
• Michigan State University — East Lansing, Michigan, United States
• Struthers Parkinson's Center — Golden Valley, Minnesota, United States
• University of Minnesota — Minneapolis, Minnesota, United States
• Washington University — St Louis, Missouri, United States
• University of Alabama at Birmingham — Birmingham, Alabama, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.